-
NLRP10 in Epidermal Homeostasis and Atopic Dermatitis
2026-09-15
The reference study identifies NLRP10 as a regulator of epidermal homeostasis rather than solely an inflammasome-associated protein. Using human atopic dermatitis material and an air-lift human skin equivalent, the authors connect NLRP10 with caspase-8-dependent keratinocyte survival, p63 stabilization, epidermal differentiation, and barrier function.
-
Hepatic sEH–Nrf2 Signaling in Osteoporosis
2026-09-15
A recent Free Radical Biology and Medicine study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase alters circulating epoxide metabolites and suppresses Nrf2-ARE antioxidant signaling during osteoclastogenesis. By combining clinical samples, ovariectomy-induced osteoporosis, liver-specific knockdown, pharmacological inhibition, metabolite analysis, and transcriptomics, the work provides a mechanistic framework for studying redox imbalance in bone remodeling.
-
AZD1390: ATM Kinase Inhibitor for Radiosensitization
2026-09-14
AZD1390 is a potent ATM kinase inhibitor for cancer research focused on DNA damage response signaling and radiation response. Its reported nanomolar cellular activity, glioma and lung cancer radiosensitization, and oral in vivo efficacy support mechanism-led studies while leaving direct effects on REV1–DHX36 biology unproven.
-
Amphotericin B: From Membrane Biology to Translation
2026-09-14
Amphotericin B is more than a potent polyene antifungal antibiotic: it is a mechanistic probe of sterol-dependent membrane integrity, innate immune signaling, and translational risk. This article outlines how researchers can convert its membrane activity into rigorous, cross-domain experimental strategies.
-
Aβ42 Peptide: Designing Better AD Assays
2026-09-13
Amyloid β-Peptide (1-42) is more than a neurotoxicity reagent: its aggregation state, cellular target, and assay context shape the biological signal. This article translates evidence from SH-SY5Y and mouse models into a decision framework for reproducible Alzheimer’s disease research.
-
Alcian Blue & Nuclear Fast Red Staining Kit
2026-09-12
The Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5, provides a two-color framework for visualizing acid mucins, mucopolysaccharides, and cell nuclei. This guide distinguishes analytical mucin staining from pre-analytical tissue marking and develops a practical strategy for chondrogenic differentiation studies.
-
Ciprofloxacin Workflows for Resistance and Nanotherapy
2026-09-11
Translate Ciprofloxacin from a benchmark fluoroquinolone antibiotic into reproducible workflows for bacterial mechanism studies and nanotheranostic assays. This guide connects DNA replication inhibition with ultrasound-activated formulation research while emphasizing solvent control, matched comparators, and preclinical limitations.
-
Amphotericin B: From Membrane Mechanism to Translation
2026-09-11
Amphotericin B remains a powerful research tool for connecting fungal membrane sterol biology with translational antifungal strategy. This article examines how ergosterol state, immune signaling, biofilm behavior, and formulation discipline can turn a conventional polyene antifungal antibiotic into a sharper mechanistic probe.
-
Neurotensin for GPCR Trafficking Studies
2026-09-10
Use Neurotensin as a defined Neurotensin receptor 1 activator to connect rapid receptor trafficking with delayed miR-133α and AFTPH readouts in gastrointestinal cell models. This workflow also adapts the reference study’s data-quality lessons, helping researchers separate biological effects from imaging, batch, and spectral-processing artifacts.
-
Atorvastatin in Ferroptosis Research Workflows
2026-09-10
Atorvastatin is a practical HMG-CoA reductase inhibitor for connecting cholesterol metabolism with vascular phenotypes and emerging ferroptosis assays. This workflow-focused guide covers solvent handling, dose selection, HCC model translation, cardiovascular applications, and troubleshooting for reproducible experiments.
-
Sumatriptan Metabolism Revisited: CYP and MAO Evidence
2026-09-09
This study re-examines the accepted metabolic pathway of sumatriptan and shows that cytochrome P450 enzymes contribute to sequential N-demethylation alongside monoamine oxidase A activity. The findings refine interpretation of sumatriptan biotransformation and provide a useful recombinant-enzyme framework for distinguishing parallel metabolic routes.
-
URB597 (KDS-4103) for FAAH Research
2026-09-09
URB597 (KDS-4103) provides selective FAAH inhibition for separating anandamide biology from broader cannabinoid pharmacology. This workflow connects target engagement with LC-MS/MS, inflammatory markers, neuronal activation, and pain-related behavior.
-
(R,S)-Anatabine Workflows for Aβ Research
2026-09-08
Build mechanism-resolved Alzheimer’s disease assays around (R,S)-Anatabine, connecting APP β-cleavage, BACE-1 expression, soluble Aβ peptide reduction, and NF-κB signaling. The workflow separates neuronal cell-based screening from acute animal-model validation while providing practical controls for solvent handling, assay timing, and endpoint interpretation.
-
Tacrine-Based Hybrids in Alzheimer’s Research
2026-09-08
This review maps tacrine-based hybrid molecules reported from 2006 to 2022 and explains how scaffold hybridization can combine cholinesterase inhibition with activities directed at amyloid aggregation, oxidative stress, metal imbalance, and related Alzheimer's disease mechanisms. Its practical value lies in connecting molecular design features with preclinical efficacy and toxicity considerations, while emphasizing that reduced hepatotoxicity and cognitive benefit still require rigorous validation.
-
Atorvastatin: HMG-CoA Reductase Inhibitor Research
2026-09-07
Atorvastatin is an orally bioavailable HMG-CoA reductase inhibitor used in cholesterol metabolism research and vascular cell biology studies. Product benchmarks include smooth-muscle-cell IC50 values and an abdominal aortic aneurysm model, while a 2025 study identifies atorvastatin as a potential ferroptosis-inducing agent in hepatocellular carcinoma rather than an established cancer therapy.